European Commission approves marketing authorisation for Biogen ’s 5q SMA treatment

The European Commission (EC) has granted marketing authorisation for US-based biotechnology company Biogen ’s Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news